PMID- 35810147
OWN - NLM
STAT- MEDLINE
DCOM- 20220809
LR  - 20220927
IS  - 1873-460X (Electronic)
IS  - 1056-8727 (Linking)
VI  - 36
IP  - 8
DP  - 2022 Aug
TI  - A new perspective on diabetes distress using the type 2 diabetes distress 
      assessment system (T2-DDAS): Prevalence and change over time.
PG  - 108256
LID - S1056-8727(22)00165-9 [pii]
LID - 10.1016/j.jdiacomp.2022.108256 [doi]
AB  - AIMS: To establish cut-points and thresholds for elevated diabetes distress; 
      document change over time; and define minimal clinically important differences 
      (MCID) using the new Type 2 Diabetes Distress Assessment System (T2-DDAS). 
      METHODS: A national sample of adults with type 2 diabetes completed the T2-DDAS 
      CORE distress scale and the 7 T2-DDAS SOURCE distress scales at baseline and 
      6-months. Scores were computed separately for insulin- and non-insulin users. 
      Spline regression models defined CORE cut-points and SEM formulas defined MCID. A 
      rational "threshold" approach defined elevated SOURCE scores. RESULTS: 471 
      participants (205 insulin, 266 non-insulin) completed both assessments. Analyses 
      yielded >/=2.0 as the cut-point for both elevated CORE and elevated SOURCE. 
      Prevalence of elevated CORE was 61.8 % (69.9 % over 6 months). Elevated SOURCE 
      scores varied from 30.6 % (Stigma/Shame) to 76.4 % (Management); 87.5 % indicated 
      at least 1 elevated SOURCE score. Most (77.1 %) reported multiple elevated 
      SOURCES. 81.8 % with elevated CORE distress at baseline remained elevated at 
      6 months. MCID analyses yielded +/- 0.25 as significant change. Few differences 
      between insulin- and non-insulin users occurred. CONCLUSIONS: Elevated CORE 
      distress is highly prevalent and persistent over time; most participants reported 
      multiple SOURCES of distress. Findings highlight the need for comprehensive 
      assessment of diabetes distress.
CI  - Copyright (c) 2022 Elsevier Inc. All rights reserved.
FAU - Fisher, L
AU  - Fisher L
AD  - University of California, San Francisco, CA, USA. Electronic address: 
      larry.fisher@ucsf.edu.
FAU - Polonsky, W H
AU  - Polonsky WH
AD  - Behavioral Diabetes Institute, San Diego, CA, USA; University of California, San 
      Diego, CA, USA.
FAU - Perez-Nieves, M
AU  - Perez-Nieves M
AD  - Eli Lilly and Company, Indianapolis, IN, USA.
FAU - Desai, U
AU  - Desai U
AD  - Analysis Group, Boston, MA, USA.
FAU - Strycker, L
AU  - Strycker L
AD  - Oregon Research Institute, Eugene, OR, USA.
FAU - Hessler, D
AU  - Hessler D
AD  - University of California, San Francisco, CA, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220705
PL  - United States
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
RN  - 0 (Insulin)
RN  - 0 (Insulin, Regular, Human)
SB  - IM
MH  - Adult
MH  - *Diabetes Mellitus, Type 1/epidemiology
MH  - *Diabetes Mellitus, Type 2/complications/epidemiology
MH  - Humans
MH  - Insulin/therapeutic use
MH  - Insulin, Regular, Human
MH  - Prevalence
OTO - NOTNLM
OT  - Change over time
OT  - Diabetes
OT  - Diabetes distress
OT  - Prevalence
EDAT- 2022/07/10 06:00
MHDA- 2022/08/10 06:00
CRDT- 2022/07/09 22:13
PHST- 2022/04/27 00:00 [received]
PHST- 2022/06/29 00:00 [revised]
PHST- 2022/06/29 00:00 [accepted]
PHST- 2022/07/10 06:00 [pubmed]
PHST- 2022/08/10 06:00 [medline]
PHST- 2022/07/09 22:13 [entrez]
AID - S1056-8727(22)00165-9 [pii]
AID - 10.1016/j.jdiacomp.2022.108256 [doi]
PST - ppublish
SO  - J Diabetes Complications. 2022 Aug;36(8):108256. doi: 
      10.1016/j.jdiacomp.2022.108256. Epub 2022 Jul 5.